CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces that its international distributors in six countries are adopting the marketing model used successfully in the U.S. of introducing the MyoPro® powered orthosis to candidates through screening days.
Myomo's Orthotics and Prosthetics (O&P) partners in Germany, Denmark, U.K., Italy, Chile and Australia have conducted or have planned screening days to demonstrate the MyoPro and evaluate individuals with arm paralysis for the devices. These firms, including nine independent O&Ps in Germany, Neuro-Muscular Orthotics (NMO) across Australia, Bandagist Jan Nielsen in the Nordic region, Hobbs Rehabilitation and Dorset Orthopaedic Company in the U.K, Tecnoplanta Orthopedic Laboratory in Chile and Progettiamo Autonomia Robotics in Italy, have multiple locations across their countries and are using social media and digital marketing as well as referrals from physicians and therapists to educate potential patients about the benefits of the MyoPro powered braces. Their activities have already resulted in an international pipeline of over 20 MyoPro devices and successful reimbursement efforts in several countries.
"In the U.S., we've found that the best way to inform chronic stroke survivors and others with upper limb paralysis that there is now a device that may restore function for them is to get the word out via platforms such as Facebook and Google. This can lead to an assessment and evaluation to determine if they are medically qualified for a MyoPro," said Jonathan Naft, Vice President and General Manager-International of Myomo. "We are pleased to see that our international partners are tailoring this approach to their home markets and their plans for over 50 screening days in the next six months."
Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding the Company's future business expectations which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, our international collaborations and potential future business internationally. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, our ability to secure and maintain reimbursement for our products, our ability to obtain additional funding to sustain and grow our business, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo's business and financial results is included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.